ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)

ClinicalTrials.gov ID: NCT03162796

Public ClinicalTrials.gov record NCT03162796. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 14, 2026, 10:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNF Alpha Agents

Study identification

NCT ID
NCT03162796
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Janssen Research & Development, LLC
Industry
Enrollment
383 participants

Conditions and interventions

Interventions

  • Guselkumab Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 23, 2017
Primary completion
Mar 13, 2019
Completion
Nov 17, 2019
Last update posted
Feb 2, 2021

2017 – 2019

United States locations

U.S. sites
9
U.S. states
8
U.S. cities
9
Facility City State ZIP Site status
Rheumatology Associates Birmingham Alabama 35205
Arizona Arthritis & Rheumatology Associates PC Glendale Arizona 85306
Arizona Arthritis & Rheumatology Research, PLLC Mesa Arizona 85210
Clinical Research Center of Connecticut Danbury Connecticut 06810
Dawes Fretzin Clinical Research Group, LLC Indianapolis Indiana 46256-4697
University of Michigan Ann Arbor Michigan 48109
Arthritis Consultants St Louis Missouri 63141
Arthritis and Osteoporosis Associates Freehold New Jersey 07728
Austin Regional Clinic Austin Texas 78731-3146

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 86 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03162796, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 2, 2021 · Synced May 14, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03162796 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →